FibroBiologics Reports Promising Preclinical Results for FSdC Therapy in Degenerative Disc Disease
HOUSTON, Jan. 5, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology firm, has announced encouraging preclinical outcomes for its FSdC spheroid therapy, aimed at treating degenerative disc disease. These results demonstrate a significant improvement in maintaining intervertebral disc integrity in animal models, marking a pivotal advancement in FibroBiologics' regenerative medicine initiatives.
Key Findings from Preclinical Study
The recent animal model study on degenerative disc disease revealed several critical results that underscore the effectiveness of FSdC spheroids:
- Improved Disc Height Recovery: FSdC spheroids achieved superior intervertebral disc height recovery at 12 weeks after treatment, outperforming both 2D fibroblasts and fibroblast spheroids.
- Statistical Superiority: The data indicated that FSdC spheroids exhibited exceptional performance, achieving an unadjusted p-value of 0.00015, compared to 0.036 for 2D fibroblasts and 0.068 for fibroblast spheroids.
- Breakthrough Potential: FSdC spheroids maintained the highest average disc size index (%DHI), suggesting a new direction in the treatment of degenerative disc disease and related joint cartilage damage.
Statements from Leadership
"These compelling preclinical results for FSdC mark a significant step forward in our regenerative pipeline and advance our goal of bringing innovative fibroblast-based therapies to patients," stated Pete O’Heeron, Founder and CEO of FibroBiologics. He emphasized the potential of FSdC spheroids to enhance structural integrity and revolutionize the management of spinal degenerative conditions.
Dr. Hamid Khoja, Chief Scientific Officer, elaborated on the findings, stating that FSdC spheroids utilize a unique regenerative activity, integrating extracellular matrix remodeling and inflammation control to restore spinal disc homeostasis.
The Need for New Treatment Options
Degenerative disc disease is a leading source of chronic pain and disability in the United States, affecting millions of adults. Current treatments often fall short in delivering long-term results. FibroBiologics aims to address these unmet medical needs with the FSdC spheroids, seeking to advance through clinical trials.
About FibroBiologics
Headquartered in Houston, FibroBiologics is focused on developing innovative therapies for chronic diseases by leveraging fibroblasts and fibroblast-derived materials. The company holds more than 270 patents, highlighting its commitment to advancing therapies across various medical fields, including wound healing and orthopedics.
For more information about FibroBiologics and its potential therapies, visit FibroBiologics.com.
Cautionary Note on Forward-Looking Statements
This announcement may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations of FibroBiologics' management and involve risks and uncertainties that could cause actual results to differ materially.